tert-butyl [(1S)-1-benzyl-2-({2-[(hydroxyamino)carbonyl]-1-benzothien-6-yl}amino)ethyl]carbamate | 913653-79-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl [(1S)-1-benzyl-2-({2-[(hydroxyamino)carbonyl]-1-benzothien-6-yl}amino)ethyl]carbamate
• 英文别名: tert-butyl N-[(2S)-1-[[2-(hydroxycarbamoyl)-1-benzothiophen-6-yl]amino]-3-phenylpropan-2-yl]carbamate
• CAS: 913653-79-9
• 化学式: C₂₃H₂₇N₃O₄S
• 分子量: 441.551
• InChiKey: NAFOEBBRSWYOHZ-SFHVURJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  128
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2,4-二硝基苯甲醛 在 palladium 10% on activated carbon 氢气 、 羟胺 、 三乙酰氧基硼氢化钠 、 potassium carbonate 、 溶剂黄146 作用下， 以 水 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 147.0h， 生成 tert-butyl [(1S)-1-benzyl-2-({2-[(hydroxyamino)carbonyl]-1-benzothien-6-yl}amino)ethyl]carbamate
  参考文献：
  名称：

  WO2006/115833

  摘要：

  公开号：

文献信息

• Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions
  申请人：Methot Joey

  公开号：US20090318541A1

  公开（公告）日：2009-12-24

  The present invention relates to a novel class of hydroxamic acid derivatives carbamate, urea, amide and sulfonamide substitutions. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.

  本发明涉及一种新型类羟肟酸衍生物，包括碳酸酯，脲，酰胺和磺酰胺取代基。这些羟肟酸化合物可用于治疗癌症。这些羟肟酸化合物也可以抑制组蛋白去乙酰化酶，并适用于有选择地诱导终末分化，阻止肿瘤细胞的生长和/或凋亡，从而抑制此类细胞的增殖。因此，本发明的化合物可用于治疗具有肿瘤细胞增殖特征的患者。该发明的化合物还可用于预防和治疗TRX介导的疾病，如自身免疫性，过敏性和炎症性疾病，以及中枢神经系统（CNS）疾病的预防和/或治疗，如神经退行性疾病。本发明还提供了包含羟肟酸衍生物的制药组合物和这些制药组合物的安全给药方案，易于遵循，并在体内产生治疗有效量的羟肟酸衍生物。
• US7872024B2
  申请人：——

  公开号：US7872024B2

  公开（公告）日：2011-01-18
• [EN] BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES WITH CARBAMATE, UREA, AMIDE AND SULFONAMIDE SUBSTITUTIONS<br/>[FR] DERIVES D'ACIDE HYDROXAMIQUE DE BENZOTHIOPHENE AVEC DES SUBSTITUTIONS CARBAMATE, UREE, AMIDE ET SULFAMIDE
  申请人：MERCK & CO INC

  公开号：WO2006115833A1

  公开（公告）日：2006-11-02

  [EN] The present invention relates to a novel class of hydroxamic acid derivatives carbamate, urea, amide and sulfonamide substitutions. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.
  [FR] La présente invention concerne une nouvelle classe de dérivés d'acide hydroxamique associés à des substitutions carbamate, urée, amide et sulfamide. Les composés d'acide hydroxamique peuvent s'utiliser dans le traitement du cancer. Les composés d'acide hydroxamique peuvent également inhiber l'histone désacétylase et sont adaptés à l'utilisation dans la différentiation terminale à induction sélective, pour empêcher la croissance cellulaire et/ou l'apoptose des cellules néoplasiques, ce qui inhibe la prolifération de ces cellules. De cette manière, les composés de la présente invention sont utiles pour traiter un patient souffrant d'une tumeur caractérisée en la prolifération de cellules néoplasiques. Les composés de l'invention sont aussi utiles dans la prévention et le traitement de maladies induites par la TRX, telles que les maladies auto-immunes, allergiques et inflammatoires, ainsi que dans la prévention et/ou le traitement de maladies du système nerveux central (SNC), telles que les maladies neurodégénératives. La présente invention concerne également des compositions pharmaceutiques comprenant des dérivés d'acide hydroxamique et des schémas posologiques sûrs de ces compositions pharmaceutiques, qui sont faciles à respecter et qui permettent d'obtenir une quantité thérapeutiquement efficace des dérivés d'acide hydroxamique in vivo.